Australien - engelsk - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - normal immunoglobulin, quantity: 1650 mg - injection, solution - excipient ingredients: polysorbate 80; water for injections; glycine; tributyl phosphate; human immunoglobulin a; sodium acetate; sodium chloride - replacement therapy in adults and children in primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency (cvid), severe combined immunodeficiencies, igg subclass deficiencies with recurrent infections. replacement therapy in myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 5 g - injection, solution - excipient ingredients: sorbitol; human immunoglobulin a; water for injections - replacement therapy indications: - primary immunodeficiency (pi) diseases - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation indications: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillain barr? syndrome - kawasaki disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 20 g - injection, solution - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy indications: - primary immunodeficiency (pi) diseases - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation indications: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillain barr? syndrome - kawasaki disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 10 g - injection, solution - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy indications: - primary immunodeficiency (pi) diseases - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,immunomodulation indications: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - guillain barr? syndrome - kawasaki disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals: - household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. - common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, administration of normal immunoglobulin-vf should be considered for all those exposed to the source. - institutional contacts. - staff in institutions where hepatitis is endemic. routine prophylaxis is not recommended for school, office, factory or hospital contacts.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals: - household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. - common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, administration of normal immunoglobulin-vf should be considered for all those exposed to the source. - insstitutional contacts. - staff in institutions where hepatitis is endemic. routine prophylaxis is not recommended for school, office, factory or hospital contacts.

Malta - engelsk - Malta Medicines Authority

octapharma (ip) limited - human normal immunoglobulin - solution for injection - human normal immunoglobulin 165 mg/ml - immune sera and immunoglobulins

Malta - engelsk - Malta Medicines Authority

octapharma (ip) limited - human normal immunoglobulin - solution for injection - human normal immunoglobulin 165 mg/ml - immune sera and immunoglobulins

Malta - engelsk - Malta Medicines Authority

octapharma (ip) limited - human normal immunoglobulin - solution for injection - human normal immunoglobulin 165 mg/ml - immune sera and immunoglobulins

Malta - engelsk - Malta Medicines Authority

octapharma (ip) limited - human normal immunoglobulin - solution for injection - human normal immunoglobulin 165 mg/ml - immune sera and immunoglobulins